143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial

Oliver Gautschi(Université Toulouse III - Paul Sabatier), Adrian F. Ochsenbein(University of Bern), Miklos Pless(Ontario Institute for Cancer Research), Nicolas Mach(University of Geneva), Q Li(Federal Statistical Office), M. Frueh(Kantonsspital St. Gallen), Patrizia Froesch(Institute of Oncology Research), Daniel Betticher, Klazien Matter‐Walstra(University of Basel), Daniel Rauch(Washington University in St. Louis)
Journal of Thoracic Oncology
April 1, 2016
10.1016/s1556-0864(16)30253-2
Cited by 0

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|Annals of Oncology|2019|1.4k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835